about
Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutationThe fragile-X premutation: a maturing perspective.Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndromeAdvances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum DisorderFragile X spectrum disordersUnstable mutations in the FMR1 gene and the phenotypesDetection and Quantification of the Fragile X Mental Retardation Protein 1 (FMRP)A review of fragile X premutation disorders: expanding the psychiatric perspectiveMouse models of fragile X-associated tremor ataxia.Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatmentArgonaute2 suppresses Drosophila fragile X expression preventing neurogenesis and oogenesis defects.Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio.Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome.Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriersNuclear accumulation of stress response mRNAs contributes to the neurodegeneration caused by Fragile X premutation rCGG repeatsAltered structural brain connectome in young adult fragile X premutation carriers.Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease.Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndromeLifespan changes in working memory in fragile X premutation males.Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families.Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment.COGNITIVE DYSFUNCTION IN FMR1 PREMUTATION CARRIERS.The FMR1 gene and fragile X-associated tremor/ataxia syndrome.Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome.A cross-sectional analysis of orienting of visuospatial attention in child and adult carriers of the fragile X premutation.Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila.Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone.Distribution and frequency of intranuclear inclusions in female CGG KI mice modeling the fragile X premutationEnhanced asynchronous Ca(2+) oscillations associated with impaired glutamate transport in cortical astrocytes expressing Fmr1 gene premutation expansionTreatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems.Size bias of fragile X premutation alleles in late-onset movement disorders.The fragile X continuum: new advances and perspectives.FMR1: a gene with three faces.Ectopic expression of CGG containing mRNA is neurotoxic in mammals.Top-down or bottom-up: Contrasting perspectives on psychiatric diagnosesMolecular pathogenesis of fragile X-associated tremor/ataxia syndromeMurine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration.Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS.Peripheral neuropathy and parkinsonism: a large clinical and pathogenic spectrum.
P2860
Q24533431-B7E01402-2DCF-4129-AA32-AB2705F452F7Q24533443-6BD31F96-F47F-4446-AF90-CDE2F38704DCQ24567980-6AC55EF1-DBEE-43B4-89F6-BB82797EFE71Q26781265-7B2E56F1-E301-4F2E-AE11-704124BF2FA9Q26824376-2EC62783-FA7A-4D29-B132-54563AC95CF1Q26996649-21BA70AB-A1AE-442A-A730-2785524EA92FQ28079967-0D019B44-788D-48A7-BA34-6AA7B09648F5Q33440958-BEDDFFB1-435A-4C3C-8B04-60B64C45EC40Q33477843-B7767447-2B9B-483C-96E0-2E477E0534E4Q33477846-2F6A3FA3-13B4-4733-A4A4-AE7BFA95EBA3Q33514846-EA4C0794-DA30-4A94-A105-212FDBF7D0D4Q33527737-40573098-71C5-4E93-9610-7AB85739C6D1Q33649463-B6993A1C-80D3-486A-B4ED-D5BE97A3A0D0Q33684243-56F84DEF-DECB-4BA1-B781-CF637B57388AQ33926845-5C4F39BC-D0AE-4EEA-83C2-26B30465219FQ33933968-95AB425E-02F1-4A33-98F4-5413B7CD4EF3Q33967902-4FBE357A-C62C-42D6-AD62-171DD7D258BCQ34055453-19759D54-0E47-46C4-A019-54A4B1426CBDQ34154343-F7F3917A-61AD-480B-AF97-B761E23A3E64Q34231104-F24478F3-7FE6-409B-84B1-1F458D90B58FQ34327177-1339DA62-1C01-4007-8A9F-947E241FF679Q34329664-DF8EB36A-BA86-47F6-A214-C42A6D9B4F1EQ35006611-E15CAFB9-6085-44CE-B723-ED7EBC2532D4Q35061671-7575C540-D6F5-4C03-89D7-0DF773744765Q35533280-5A50204E-4EF3-4A75-98CB-9218182F3CD9Q35559347-3D2941DB-304E-4E80-8759-E499052E3E27Q35860358-8B66A124-3A41-4BB6-9812-3D2650D2B262Q36026897-8E69C413-B3F6-4EFD-8CC2-A55EE2D838D6Q36611172-5608AAAA-1C6A-407F-BB98-8FFAC68F8949Q36832709-40D290AB-8FDA-4EB2-8214-93013AED709CQ36897434-DD4874F6-FCF5-4028-A6C0-DA0B14F07198Q36927093-15E0F661-7251-4F1E-BB07-2BCC58E584BFQ37150380-C0E95AC5-750E-47B9-9376-AD4F215649A0Q37216636-072B3648-5E82-4545-9FA2-4ABB56442DFAQ37223278-F65011C8-234E-42FB-B0FC-55FC41A45054Q37290726-6381CA39-D6CD-453B-9AA1-9E7621A7F53AQ37455479-5F3D8D9B-8C9B-4540-907F-571F5DCFFDA4Q37471792-EA1D4D5E-2ADA-4F0E-BE25-51698D65AFC2Q37663133-8B5D2E7D-DAA4-4EC0-BEDD-21923D1E74F0Q38316108-58D91E18-2619-4C7F-BF48-950655409084
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Aging in individuals with the FMR1 mutation.
@ast
Aging in individuals with the FMR1 mutation.
@en
type
label
Aging in individuals with the FMR1 mutation.
@ast
Aging in individuals with the FMR1 mutation.
@en
prefLabel
Aging in individuals with the FMR1 mutation.
@ast
Aging in individuals with the FMR1 mutation.
@en
P2093
P2860
P1476
Aging in individuals with the FMR1 mutation.
@en
P2093
E Berry-Kravis
P J Hagerman
P2860
P304
P356
10.1352/0895-8017(2004)109<154:AIIWTF>2.0.CO;2
P577
2004-03-01T00:00:00Z